Digging the Latest Small Business News

Revolutionary Obesity and Diabetes Research Earns Trio Prestigious €1 Million Broermann Award

/Pioneering Scientists Recognized for Breakthroughs in Obesity and Diabetes Therapies

Key Points:
– Prof. Svetlana Mojsov, Prof. Dr. Richard DiMarchi, and Prof. Dr. Dr. h.c. Matthias H. Tschöp awarded the prestigious Broermann Medical Innovation Award 2026.
– The award, presented by Minister-President Boris Rhein, honors their contributions to GLP-1-based therapies for obesity and diabetes.
– The winners’ research has significantly advanced treatment options, impacting the lives of millions worldwide.
– The nomination phase for the 2027 award has opened, inviting global submissions until March 1, 2027.

Wiesbaden – The Broermann Medical Innovation Award 2026 has been awarded to Prof. Svetlana Mojsov from The Rockefeller University, Prof. Dr. Richard DiMarchi from Indiana University, and Prof. Dr. Dr. h.c. Matthias H. Tschöp from Ludwig-Maximilians-Universität München. The distinguished accolade, which includes a total endowment of one million euros, was presented by Hessian Minister-President Boris Rhein during a ceremony at the Hessian State Chancellery.

This prestigious honor recognizes the groundbreaking research conducted by the laureates, which has been instrumental in the development of modern GLP-1-based therapies designed to treat obesity and diabetes. The award was established by Dr. Bernard große Broermann, founder of the Asklepios Kliniken Group.

In his address, Minister-President Rhein highlighted the monumental impact of their scientific contributions: “Through their research, Prof. Dr. Richard D. DiMarchi, Prof. Dr. Svetlana Mojsov, and Prof. Dr. med. Dr. h.c. Matthias Tschöp have opened a new chapter in metabolic therapy. Their work laid the scientific foundation for what is colloquially known as the ‘weight-loss injection.’ From fundamental insights into human metabolism, a new generation of therapies has emerged, paving the way for effective treatments for diabetes and obesity, while also helping to manage or reduce associated secondary conditions.”

Prof. Dr. Werner Seeger, the Chairman of the Jury for the Broermann Award, remarked on the significance of their findings, stating: “The work of this year’s laureates powerfully proves how scientific pioneering transforms into medical reality. Their discoveries surrounding GLP-1 and polyagonists have fundamentally redefined obesity and diabetes care, offering real hope to millions worldwide.”

The laureates expressed their gratitude for the recognition. Prof. Svetlana Mojsov commented, “I am humbled and honored to receive the Broermann Award for my work on GLP-1 that began over 40 years ago with a hypothesis and has gone to benefit the health and lives of millions of people worldwide.” Prof. Dr. Richard DiMarchi added, “In the last decade, based upon a half century of research we have progressed with incretin-based medicines to transform the management of excess body weight analogous to historical treatment of excess glucose, cholesterol, and blood pressure. It is providing a transformative advance in public health and patient well-being.” Meanwhile, Prof. Dr. Dr. h.c. Matthias H. Tschöp expressed his honor in receiving the award: “It is a great honor to receive this recognition together with Svetlana Mojsov and Richard DiMarchi. We are delighted that our decades of work on the scientific foundation and invention of therapeutic principles that ignited the modern obesity-drug revolution is receiving international recognition.”

Titia Olivia große Broermann, a Shareholder of the Asklepios Kliniken Group, emphasized the award’s significance, stating: “The Broermann Medical Innovation Award stands for the conviction that medical progress begins where scientific courage meets the determination to sustainably improve patients’ lives. This year’s awardees impressively demonstrate how scientific curiosity and decades of research can give rise to therapies that transform the lives of millions of people.”

The contributions of Prof. Mojsov, Prof. DiMarchi, and Prof. Tschöp have established the groundwork for a new generation of therapies designed to regulate weight and control blood sugar, significantly enhancing treatment options for patients.

The nomination phase for the Broermann Medical Innovation Award 2027 is now open, allowing scientists globally to submit nominations until March 1, 2027. Further information regarding the award and nomination criteria is available on the official website.

Share this article
0
Share
Shareable URL
Prev Post

Whitstable Audiologist Crowned UK Supervisor of the Year, Elevating Local Hearing Care

Next Post

Taiwan Unveils Groundbreaking Digital Healthcare Innovations at MEDICA 2026

Read next
0
Share